Scarica l'app Stockscreener
115.00
0.10%
0.11
Dopo l'orario di chiusura:
115.00
Precedente Chiudi:
$114.89
Aprire:
$114.89
Volume 24 ore:
588.89K
Relative Volume:
0.28
Capitalizzazione di mercato:
$6.73B
Reddito:
$22.29M
Utile/perdita netta:
$-228.93M
Rapporto P/E:
-28.36
EPS:
-4.0547
Flusso di cassa netto:
$-212.59M
1 W Prestazione:
+0.18%
1M Prestazione:
+0.53%
6M Prestazione:
+24.50%
1 anno Prestazione:
+87.20%
Intervallo 1D:
$114.87
$115.10
Intervallo di 1 settimana:
$114.77
$115.10
Portata 52W:
$47.86
$115.10
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
115.00 | 6.72B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-22 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
Arcellx stock hits all-time high of 114.95 USD By Investing.com - Investing.com Canada
Profit Recap: Does Arcellx Inc stock have upside surprise potential2026 Momentum & Low Drawdown Investment Ideas - baoquankhu1.vn
Short Squeeze: Is Arcellx Inc stock heavily shorted2026 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
ACLX Stock Price, Quote & Chart | ARCELLX INC (NASDAQ:ACLX) - ChartMill
Sell Signal: Can Arcellx Inc be the next market leader2026 Reactions & Fast Momentum Entry Tips - baoquankhu1.vn
Shorts Report: Can Arcellx Inc grow without external funding2026 Retail & Stock Market Timing Techniques - baoquankhu1.vn
With 3 quick buyouts, Gilead leans into its latest transformation - BioPharma Dive
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities - BioSpace
Assessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
(ACLX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Sahm
Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom - MarketBeat
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline ExpansionSlideshow (NASDAQ:GILD) 2026-04-07 - Seeking Alpha
GILD: Acquisitions of Tubulis, Ouro, and Arcellx add best-in-class assets and platforms for sustained growth - TradingView — Track All Markets
GILD: Acquisitions of Tubulis, Ouro, and Arcellx drive pipeline growth and market expansion - TradingView — Track All Markets
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
ArcellxTech Details - Crunchbase
Key facts: Gilead Extends Arcellx Deal; $115+CVR; HIV Coverage Varies - TradingView
ACLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arcellx, Inc. (ACLX) stock price, news, quote and history - Yahoo Finance UK
Gilead Extends Tender Offer to Acquire Arcellx - BioSpace
Gilead extends Arcellx tender offer expiration date - MSN
Gilead Sciences Extends Tender Offer for Arcellx Shares to April 14, 2026 - geneonline.com
Arcellx Inc stock hits all-time high at 114.92 USD By Investing.com - Investing.com Canada
Gilead Extends Tender Offer To Acquire Arcellx - TradingView
Gilead Sciences, Arcellx see HSR waiting period expire March 31 - mlex.com
Arcellx (ACLX) 14D-9 amendment: Offer extended to Apr 24; HSR waiting period ended - Stock Titan
Gilead (NASDAQ: ACLX) extends $115 per‑share tender, CVR pays $5 on condition - Stock Titan
Arcellx (NASDAQ:ACLX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Arcellx Inc stock hits all-time high at 114.92 USD - Investing.com
ACLX PE Ratio & Valuation, Is ACLX Overvalued - Intellectia AI
Piper Sandler Downgrades Arcellx(ACLX.US) to Hold Rating, Maintains Target Price $115 - Moomoo
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Gilead to buy US biotech Arcellx for up to $7.8 billion - msn.com
Aug PreEarnings: How does Arcellx Inc compare to its peersWeekly Loss Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
MACD Signal: What hedge funds are buying Arcellx Inc2026 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data - simplywall.st
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Gilead’s Arcellx Deal Deepens Oncology Focus And Reshapes Investor Risk Profile - Sahm
Price-Driven Insight from (ACLX) for Rule-Based Strategy - Stock Traders Daily
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook? - Yahoo Finance
ARCELLX PB Ratio: 16.50 — 103% Above Median - GuruFocus
Vanguard Realignment: Arcellx (ACLX) Beneficial Ownership Reported as 0% - Stock Titan
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Assessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price Momentum - Yahoo Finance
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Trade Report: Can Arcellx Inc maintain its current growth rateRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):